Skip to main content
Smart Investors Daily
Incyte Corporation logo

NASDAQ · INCY

Incyte Corporation

Healthcare · Biotechnology

$115.87

Down-$1.93 (-1.64%)

Updated Nov 20, 2026, 2:27 AM

SID Score

6.5/10

Composite research score

Smart Money

58/100

Neutral

Market cap
18.86B
P/E ratio
15.82
Dividend yield
0.00%
52-week range
$89.25 – $132.60
Volume
1.18M
Avg. volume
2.2M

Price performance · INCY

INCY price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

INCY closed at $115.87 after 21 trading sessions, down 0.91% for the selected period.

Last close
$115.87
Period change
-0.91%
Period low
$113.31
Period high
$122.85
Daily close
View OHLC price history
INCY OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$117.80$118.43$115.5001$115.871.18M
Nov 18, 2026$118.77$120.99$117.76$117.801.21M
Nov 17, 2026$119.95$121.43$118.05$119.092.25M
Nov 16, 2026$121.98$122.94$119.79$120.271.51M
Nov 13, 2026$121.89$122.065$119.72$120.97950.51K
Nov 12, 2026$123.09$123.90$121.29$121.701.01M
Nov 11, 2026$119.37$122.73$117.84$122.271.19M
Nov 10, 2026$120.58$121.25$119.03$120.301.8M
Nov 9, 2026$120.59$122.07$118.26$121.891.15M
Nov 6, 2026$116.375$119.81$115.00$119.651.49M
Nov 5, 2026$123.96$123.96$117.88$118.011.6M
Nov 4, 2026$117.52$123.33$117.52$122.852.14M
Nov 3, 2026$118.96$121.26$117.265$117.592.17M
Nov 2, 2026$119.02$121.5196$118.25$120.041.75M
Oct 30, 2026$120.10$122.8695$119.55$120.392.84M
Oct 29, 2026$111.64$117.09$111.01$116.803.05M
Oct 28, 2026$115.50$118.49$114.74$116.871.81M
Oct 27, 2026$111.18$116.76$111.18$116.602.23M
Oct 26, 2026$115.485$115.925$112.745$113.312.26M
Oct 23, 2026$116.75$116.865$115.12$115.711.48M
Oct 22, 2026$113.93$117.17$112.76$116.932.24M

Latest INCY news

The latest Smart Investors Daily articles mentioning INCY.

INCY research

Overview

Company profile and research snapshot.

Company profile

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$98.88
Implied upside
—
Analysts
—
INCY recent ratings
DateFirmRatingTarget
Nov 5, 2026Leerink PartnersOutperform—
Nov 2, 2026BernsteinMarket Perform—
Oct 30, 2026RBC CapitalSector Perform—
Oct 30, 2026Wells FargoEqual-Weight—
Oct 30, 2026BarclaysOverweight—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 13, 2026

How Incyte Trial And New Cancer Data Will Impact Natera Stock

Natera announced several updates in early November 2026, including new Signatera clinical data across multiple tumor types and a fresh collaboration with Incyte on a Phase II colorectal cancer study that uses Signatera as both a primary and secondary endpoint. The new colorectal cancer trial design, which enrolls patients based on Signatera minimal residual disease status, highlights how Natera is embedding its assay directly into treatment decision frameworks and potentially into future...

Yahoo · Nov 13, 2026

Natera (NTRA) Following Clinical Momentum Looks Fully Valued To Some

Clinical momentum puts Natera in focus Natera (NTRA) is back on traders’ screens after fresh clinical momentum. A new colorectal cancer trial with Incyte centers on the Signatera minimal residual disease test as both a primary and a secondary endpoint. Natera’s recent clinical updates arrive after a choppy few weeks for the shares, with a 7 day share price return of down 11.22% and a 30 day share price return of down 18.38%. At the same time, the year to date share price return is 41.12% and...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.